4D Molecular Therapeutics, Inc. (FDMT)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
David Kirn
Employees:
78
5858 HORTON STREET #455, EMERYVILLE, CA 94608
5105052680

We are a clinical-stage gene therapy company pioneering the development of product candidates using our targeted and evolved AAV vectors. We seek to unlock the full potential of gene therapy using our platform, Therapeutic Vector Evolution, which combines the power of directed evolution with our approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products.

Data derived from most recent annual or quarterly report
Market Cap 251.004 Million Shares Outstanding32.139 Million Avg 30-day Volume 237.535 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.89
Price to Revenue39.2111 Debt to Equity0.0477 EBITDA-67.715 Million
Price to Book Value2.2165 Operating Margin-395.4596 Enterprise Value407.079 Million
Current Ratio15.686 EPS Growth0.709 Quick Ratio15.169
1 Yr BETA 1.499 52-week High/Low 36.14 / 7.13 Profit Margin-395.3709
Operating Cash Flow Growth-35.7992 Altman Z-Score11.7223 Free Cash Flow to Firm -89.167 Million
Earnings Report2022-08-11
View SEC Filings from FDMT instead.

View recent insider trading info

Funds Holding FDMT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding FDMT BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BIZILY SCOTT CHIEF LEGAL OFFICER

  • Officer
0 2022-03-21 1

FISHMAN ROBERT S CHIEF MEDICAL OFFICER

  • Officer
65,000 2022-02-01 1

MORETTI AUGUST J CHIEF FINANCIAL OFFICER

  • Officer
67,000 2022-02-01 1

KAMAL FARIBORZ SEE REMARKS

  • Officer
70,000 2022-02-01 1

KIRN DAVID CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
  • 10% Owner
2,150,000 2022-02-01 1

ZIMMERMANN CAROLYNE CHIEF BUSINESS OFFICER

  • Officer
35,000 2022-02-01 3

SCHAFFER DAVID

  • Director
901,215 2021-10-20 3

MILLIGAN JOHN F

  • Director
33,750 2021-05-17 0

CHACKO JACOB

  • Director
22,500 2021-05-17 0

TOMASELLO SHAWN

  • Director
22,500 2021-05-17 0

THEUER CHARLES

  • Director
22,500 2021-05-17 0

MILLER-RICH NANCY

  • Director
22,500 2021-05-17 0

GRAY SUSANNAH

  • Director
22,500 2021-05-17 0

VIKING GLOBAL INVESTORS LP

VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

VIKING GLOBAL OPPORTUNITIES GP LLC

HALVORSEN OLE ANDREAS

OTT DAVID C.

SHABET ROSE SHARON

  • 10% Owner
5,942,495 2020-12-15 0

YAO TONY DUNG LING

  • Director
1,063,744 2020-12-15 0

BURKOTH WILLIAM T.

  • Director
0 2020-12-10 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
4D MOLECULAR THERAPEUTICS IN FDMT 2022-05-20 22:15:03 UTC 0.3 0.52 200000
4D MOLECULAR THERAPEUTICS IN FDMT 2022-05-20 21:45:03 UTC 0.3 0.52 200000
4D MOLECULAR THERAPEUTICS IN FDMT 2022-05-20 21:15:03 UTC 0.3 0.52 200000
4D MOLECULAR THERAPEUTICS IN FDMT 2022-05-20 20:45:03 UTC 0.3 0.52 200000
4D MOLECULAR THERAPEUTICS IN FDMT 2022-05-20 20:15:05 UTC 0.3 0.52 200000
4D MOLECULAR THERAPEUTICS IN FDMT 2022-05-20 19:45:03 UTC 0.3 0.52 200000
4D MOLECULAR THERAPEUTICS IN FDMT 2022-05-20 19:15:04 UTC 0.3 0.52 200000
4D MOLECULAR THERAPEUTICS IN FDMT 2022-05-20 18:45:03 UTC 0.3 0.52 200000
4D MOLECULAR THERAPEUTICS IN FDMT 2022-05-20 18:15:03 UTC 0.3 0.52 200000
4D MOLECULAR THERAPEUTICS IN FDMT 2022-05-20 17:45:03 UTC 0.3 0.52 200000
4D MOLECULAR THERAPEUTICS IN FDMT 2022-05-20 17:15:03 UTC 0.3 0.52 200000
4D MOLECULAR THERAPEUTICS IN FDMT 2022-05-20 16:45:04 UTC 0.319 0.501 200000
4D MOLECULAR THERAPEUTICS IN FDMT 2022-05-20 16:15:03 UTC 0.319 0.501 200000
4D MOLECULAR THERAPEUTICS IN FDMT 2022-05-20 15:45:03 UTC 0.319 0.501 200000
4D MOLECULAR THERAPEUTICS IN FDMT 2022-05-20 15:15:03 UTC 0.319 0.501 200000
4D MOLECULAR THERAPEUTICS IN FDMT 2022-05-20 14:45:03 UTC 0.2074 0.6126 200000
4D MOLECULAR THERAPEUTICS IN FDMT 2022-05-20 14:15:04 UTC 0.2074 0.6126 200000
4D MOLECULAR THERAPEUTICS IN FDMT 2022-05-20 13:45:03 UTC 0.2074 0.6126 200000
4D MOLECULAR THERAPEUTICS IN FDMT 2022-05-20 13:15:03 UTC 0.2074 0.6126 200000
4D MOLECULAR THERAPEUTICS IN FDMT 2022-05-20 12:45:03 UTC 0.2074 0.6126 200000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund FDMT -100.0 shares, $-2194.0 2021-12-31 N-PORT

Elevate your investments